One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Molecular Biology Enzymes, Kits and Reagents Market

[ 英語タイトル ] Molecular Biology Enzymes, Kits and Reagents Market - Growth, Trends, and Forecast (2020 - 2025)

Product Code : MDHC0083101
Survey : Mordor Intelligence
Publish On : November, 2020
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
- Agilent Technologies
- F. Hoffmann-La Roche Ltd
- Illumina Inc.
- Lucigen Corporation
- Merck KGaA
- New England Biolabs
- Promega Corporation
- Qiagen NV
- Takara Bio Inc.
- Thermo Fisher Scientific

[Report Description]

Research & Development (R&D) is defined as the process of creating new products, processes, and technologies that can be used and marketed for mankind’s benefit in the future. The increase in R&D investment in Asia, particularly China, and the consecutive annual growth in R&D spending in North America indicate a period of stability, security, and healthy competition, across the industrial sectors. As per the 2019 Global R&D funding forecast, the annual study published by R&D magazine, a publication of Advantage Business Marketing revealed that global R&D investment has increased by around 3.6% in 2019 to a total of USD 2.3 trillion, in purchasing power parity (PPP) values for the more than 110 countries having significant R&D investments (more than $100 million). Thus, increased research and R&D investments in the life science industry are augmenting the growth of the market.

In addition, technological advancements, and rising incidence of infectious diseases and genetic disorders are some factors that are spurring the growth of the market.

Key Market Trends

Polymerase Chain Reaction Segment is Expected to Show Better Growth in the Forecast Years

Based on the Application, it is segmented into polymerase chain reaction (PCR), sequencing, epigenetics, and other applications. The growth of the segment is mainly attributed to the increasing prevalence of genetic, infectious, and chronic diseases. PCR based tests are increasingly being used to guide patient management, particularly in the fields of infectious disease, cancer, and congenital abnormalities. According to the WHO, cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. The PCR techniques are routinely used for tumor profiling and detection of bacterial infections. Pertaining to broad applications of PCR in the field of molecular biology, the market segment is expected to show better growth during the forecast period.

North America is Expected to Dominate the Market

The molecular biology enzymes, kits and reagents market dominates the North America region due to increasing prevalence of genetic and chronic disorders, such as cancer, and favorable government initiatives. According to the American Cancer Society, approximately 1,735,350 new cancer cases were diagnosed in the United States in 2018 and there were around 609,640 deaths during the same year. Furthermore, growing geriatric population, along with rising R&D activities in the region is expected to drive the market over the forecast period.

Competitive Landscape

The global players into the molecular biology enzymes, kits, and reagents market are Agilent Technologies, Inc., F.Hoffmann-La Roche Ltd., Illumina, Inc., Lucigen Corporation, Merck KGaA, New England Biolabs, Promega Corporation, Qiagen NV, Takara Bio Inc. and Thermo Fisher Scientific.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- Report customization as per the client's requirements
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence of Infectious Diseases and Genetic Disorders
4.2.2 Increasing R&D Activities in the Life Science Industry
4.2.3 Technological Advancements
4.3 Market Restraints
4.3.1 High Cost and Limited Reimbursements for Genetic Testing
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Product
5.1.1 Enzymes
5.1.2 Kits and Reagents
5.2 By Application
5.2.1 Polymerase Chain Reaction
5.2.2 Sequencing
5.2.3 Epigenetics
5.2.4 Other Applications
5.3 By End Users
5.3.1 Hospitals and Diagnostic Centers
5.3.2 Academic and Research Institutes
5.3.3 Pharmaceutical and Biotechnology Companies
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Agilent Technologies
6.1.2 F. Hoffmann-La Roche Ltd
6.1.3 Illumina Inc.
6.1.4 Lucigen Corporation
6.1.5 Merck KGaA
6.1.6 New England Biolabs
6.1.7 Promega Corporation
6.1.8 Qiagen NV
6.1.9 Takara Bio Inc.
6.1.10 Thermo Fisher Scientific




Recommended reports